MSTN and Abdominal obesity: Unfortunately, we did not include measurements of subcutaneous fat mass when designing the study because previous research indicated that myostatin knockout or inhibition reduced epididymal, retroperitoneal, and subcutaneous fat mass to the same extent [1], [6], [9], and because of the consensus that central obesity is a more important determinant of metabolic problems than subcutaneous obesity.